Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial

PURPOSE: Addressing the epidermal growth factor receptor (EGFR)-pathway by the competitive receptor ligand cetuximab is a promising strategy in pancreatic cancer. In the prospective randomized controlled phase II PARC-study (PARC: Pancreatic cancer treatment with radiotherapy (RT) and cetuximab), we...

Descripción completa

Detalles Bibliográficos
Autores principales: Liermann, Jakob, Munter, Marc, Naumann, Patrick, Abdollahi, Amir, Krempien, Robert, Debus, Juergen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921472/
https://www.ncbi.nlm.nih.gov/pubmed/35300246
http://dx.doi.org/10.1016/j.ctro.2022.03.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921472/
https://www.ncbi.nlm.nih.gov/pubmed/35300246
http://dx.doi.org/10.1016/j.ctro.2022.03.003

Ejemplares similares